Literature DB >> 16533802

Triplet chemotherapy for malignant pericardial mesothelioma: a case report.

Riichiroh Maruyama1, Maki Sakai, Tomomi Nakamura, Ryuichi Suemitsu, Tatsuro Okamoto, Hiroshi Wataya, Kenichi Nishiyama, Toshiaki Kamei, Yukito Ichinose.   

Abstract

Malignant pericardial mesothelioma (MPM) is a relatively rare neoplasm in Japan, and no standard treatment regimens have been established for this disease. A 47-year-old woman with MPM presenting with cardiac tamponade was treated using four cycles of chemotherapy consisting of cisplatin (CDDP) 40 mg/m2, gemcitabine (GEM) 800 mg/m2 and vinorelbine (VNR) 20 mg/m2 on days 1 and 8 every 4 weeks after pericardial drainage alone. The diagnosis of MPM was confirmed by an immunohistochemical procedure using either positive or negative markers of malignant mesothelioma in addition to conventional cytological examinations using pericardial effusion. The patient experienced no severe non-hematological or hematological toxicities except for grade 3 neutropenia. The patient has returned to her usual activities and has remained well for 24 months after the last chemotherapy without any evidence of disease progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533802     DOI: 10.1093/jjco/hyl003

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  10 in total

1.  A rare cause of heart failure with preserved ejection fraction: primary pericardial mesothelioma masquerading as pericardial constriction.

Authors:  Russell Fernandes; Shravan Nosib; Dorothy Thomson; Nick Baniak
Journal:  BMJ Case Rep       Date:  2014-03-20

Review 2.  Primary pericardial mesothelioma unique case and literature review.

Authors:  Muhammad Rizwan Sardar; Catherine Kuntz; Toralben Patel; Wajeeha Saeed; Eric Gnall; Shotaro Imaizumi; Leah Lande
Journal:  Tex Heart Inst J       Date:  2012

3.  Malignant pericardial mesothelioma : A systematic review of current practice.

Authors:  S Cao; S Jin; J Cao; J Shen; H Zhang; Q Meng; B Pan; Y Yu
Journal:  Herz       Date:  2017-01-27       Impact factor: 1.443

4.  Primary malignant pericardial mesothelioma-a rare cause of superior vena cava thrombosis and constrictive pericarditis.

Authors:  Wenhui Gong; Xiaofeng Ye; Kaihu Shi; Qiang Zhao
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

5.  Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report.

Authors:  Sang Mi Chung; Seong Ji Choi; Min Jung Kim; Jung Yoon Choi; Hong Jun Kim; Suk-Young Lee; Eun Joo Kang
Journal:  Oncol Lett       Date:  2016-05-17       Impact factor: 2.967

6.  A case report of an extremely rare and aggressive tumor: primary malignant pericardial mesothelioma.

Authors:  Xiaolan Feng; Liena Zhao; Guangming Han; Moosa Khalil; Francis Green; Travis Ogilvie; Vanessa Krause
Journal:  Rare Tumors       Date:  2012-04-13

7.  Desmoplastic malignant mesothelioma of the pericardium: Description of a case and review of the literature.

Authors:  Antonello Nicolini; Alessandro Perazzo; Sergio Lanata
Journal:  Lung India       Date:  2011-07

8.  18F-fluorodeoxyglucose imaging of primary malignant pericardial mesothelioma with concurrent pericardial and pleural effusions and bone metastasis: A case report.

Authors:  Xiaohui Li; Rugang Lu; Youcai Zhao; Feng Wang; Guoqiang Shao
Journal:  Mol Clin Oncol       Date:  2018-04-12

9.  Primary malignant pericardial mesothelioma - a rare cause of pericardial effusion and consecutive constrictive pericarditis: a case report.

Authors:  Thomas Butz; Lothar Faber; Christoph Langer; Jan Körfer; Oliver Lindner; Andrea Tannapfel; Klaus-Michael Müller; Axel Meissner; Gunnar Plehn; Hans-Joachim Trappe; Dieter Horstkotte; Cornelia Piper
Journal:  J Med Case Rep       Date:  2009-09-17

10.  Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry?

Authors:  Brent D Kerger; Robert C James; David A Galbraith
Journal:  Front Genet       Date:  2014-05-30       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.